Evidence analysisOctober 29, 2026Health & Science
Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 77, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
Opdivo (Nivolumab) – European Public Assessment Report Evidence Dossier
What is established
Opdivo, whose active substance is nivolumab, is an immune checkpoint inhibitor authorized by the European Medicines Agency (EMA) for the treatment of several advanced cancers. Opdivo targets PD-1, a receptor on immune T cells, preventing cancer cells from switching off T cell activity and thus enhancing immune response against tumors. It is indicated mainly for adults with advanced, metastatic, or unresectable cancers including:
- Melanoma (including in adolescents aged 12 and older)
- Non-small cell lung cancer (NSCLC)
- Advanced renal cell carcinoma
- Classical Hodgkin lymphoma (ages 5-30 in some cases)
- Squamous cell cancer of head and neck
- Urothelial cancer
- Malignant pleural mesothelioma
- Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer
- Oesophageal and gastro-oesophageal junction cancers
- Gastric cancer
- Hepatocellular carcinoma (HCC)
Studies indicate that Opdivo can be used alone or with other cancer medications and may be applied as neoadjuvant (before surgery), adjuvant (after surgery), or palliative treatment depending on cancer type and stage.
What the source claims
The EMA assessment highlights several clinical trial findings demonstrating benefits of Opdivo in prolonging survival and delaying disease progression across multiple cancer types:
- In untreated advanced melanoma, Opdivo improved 12-month survival to 73% vs 42% with dacarbazine (an older chemotherapy).
- In pre-treated melanoma, the response rate to Opdivo was approximately 32%, more than double that of comparison treatments.
- Adjuvant Opdivo after surgery in high-risk melanoma led to longer periods without recurrence than ipilimumab or placebo.
- Opdivo combined with ipilimumab further improved progression-free survival in advanced melanoma compared to either drug alone, especially in tumors with low PD-L1 expression.
- In advanced NSCLC (both squamous and non-squamous), Opdivo extended overall survival compared to docetaxel.
- In neoadjuvant NSCLC, Opdivo plus chemotherapy increased rates of complete tumor removal at surgery and extended recurrence-free survival compared to chemotherapy alone or placebo.
- For advanced renal cell carcinoma, Opdivo improved outcomes compared with everolimus, another targeted therapy.
Treatment requires prescription and specialist management due to possible severe side effects.
What may be missing from the usual framing
While the EMA summary emphasizes Opdivo’s clinical benefits and approvals, it omits detailed discussion on:
- Long-term safety profiles and frequency/severity of immune-related adverse events which can be serious and necessitate treatment delays or discontinuation.
- Cost considerations and access disparities within the European Union healthcare systems potentially affecting real-world use.
- Comparative effectiveness with other immunotherapies or emerging treatments outside of the trial comparator arms.
- Patient subgroups who may gain limited benefit, such as those with low or negligible PD-L1 tumor expression or different genetic backgrounds.
- The full spectrum of side effects, which can involve inflammation of normal tissues due to immune activation, and require careful management.
Competing evidence or uncertainty
The clinical trials summarized by EMA represent the manufacturer’s submissions reviewed during authorization. Independent data or real-world studies may provide additional insight regarding efficacy and tolerability across diverse populations. Some areas of uncertainty include:
- Variability in response rates based on tumor PD-L1 expression and genetic markers remains debated.
- The magnitude of benefit beyond median survival times and in long-term survivors is not uniformly clear across all cancer types.
- Optimal sequencing and combination with other therapies continue to evolve as new immuno-oncology drugs enter the market.
- There is limited published evidence in pediatric populations outside the indications specifically approved for classical Hodgkin lymphoma and melanoma adolescents.
Further studies are needed to clarify the balance of benefits versus risks in broader patient groups.
Why it matters
Opdivo is among the first wave of immunotherapies that have transformed cancer treatment paradigms by harnessing the immune system rather than relying solely on chemotherapy or radiation. Its approvals across multiple advanced and hard-to-treat cancers offer new hope for patients with limited options. Understanding the evidence behind its use helps patients, clinicians, and policymakers make informed decisions regarding treatment choices, healthcare resource allocation, and ongoing research priorities. Transparency regarding both benefits and limitations fosters realistic expectations and safe usage.
What to verify next
- Look for independent peer-reviewed publications detailing long-term safety and efficacy of Opdivo in broader clinical practice beyond trials.
- Examine real-world data registries to assess patient outcomes and adverse event rates in diverse healthcare settings.
- Review cost-effectiveness analyses within different EU states to understand access and reimbursement policies.
- Seek updates on new comparative studies involving Opdivo versus other immunotherapies or novel agents.
- Monitor emerging evidence regarding biomarkers predicting which patients respond best to Opdivo.
Readers are encouraged to consult the original European Medicines Agency public assessment report for full detailed information on Opdivo’s clinical data, regulatory status, and product information.
Source & verification
Primary source: What's new · October 29, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…